[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":497},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,48,68,95,120,145,172,191,216,241,267,295,320,345,374,398,423,446,475],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100620470","effect-of-post-suction-recruitment-on-lung-volume-in-mechanically-ventilated-icu-patients-100620470",false,"NCT07358039","Effect of Post-suction Recruitment on Lung Volume in Mechanically Ventilated ICU Patients","Impact of a Recruitment Maneuver After Closed Endotracheal Suctioning on End-expiratory Lung Volume in Mechanically Ventilated ICU Patients Assessed by Electrical Impedance Tomography","RESPIRE","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Covered by national health insurance\n* Admitted to the intensive care unit\n* Intubated and mechanically ventilated\n* Neuromuscular blockade at inclusion\n* Written informed consent obtained from a legally authorized representative or next of kin\n\nExclusion Criteria:\n\n* Contraindication to electrical impedance tomography (e.g. pacemaker, implantable cardioverter-defibrillator, or implanted electrical stimulation device)\n* Contraindication to recruitment maneuvers (e.g. emphysema, undrained pneumothorax, hemodynamic instability)\n* Refractory intracranial hypertension\n* Acute respiratory distress syndrome requiring prone positioning\n* Pregnant or breastfeeding women\n* Patients deprived of liberty or under legal protection\n* Any condition judged by the investigator to interfere with study evaluation","ALL","18 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients who are intubated and mechanically ventilated in the intensive care unit (ICU) require repeated endotracheal suctioning to remove airway secretions. Although this procedure is necessary, it can cause a temporary collapse of lung units (alveolar derecruitment), leading to a decrease in lung volume and impaired oxygenation.\n\nA recruitment maneuver consists of briefly applying a higher airway pressure after suctioning in order to reopen collapsed lung areas and restore lung volume. However, the clinical benefit of performing a recruitment maneuver systematically after suctioning remains uncertain.\n\nThis study aims to evaluate whether performing a recruitment maneuver immediately after closed-circuit endotracheal suctioning improves lung volume compared with suctioning alone. Lung volume will be assessed using electrical impedance tomography (EIT), a non-invasive bedside imaging technique that allows real-time monitoring of lung aeration.\n\nIn a randomized crossover design, each patient will undergo two suctioning procedures: one followed by a recruitment maneuver and one without, in a random order. The main outcome will be the change in end-expiratory lung volume 15 minutes after suctioning. The results may help optimize ventilatory care in mechanically ventilated ICU patients.",[27],"Mechanical Ventilation",[29,30,31,32,33,34],"Endotracheal suction","Alveolar recruitment","Electrical impedance tomography","End-expiratory lung volume","Intensive care","Mechanical ventilation","RECRUITING","2026-06-15",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":39},"2026-04-02",{"date":43,"type":21},"2027-04",{"name":45,"class":46},"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":47},"100622142","evaluation-of-the-reliability-of-aar-as-an-independent-tool-for-surgical-indication-in-nasal-obstruction-100622142","NCT07379775","Evaluation of the Reliability of AAR as an Independent Tool for Surgical Indication in Nasal Obstruction","Evaluation of the Reliability of Anterior Active Rhinomanometry as an Independent Tool for Surgical Indication in Nasal Obstruction","RHINOVE","Inclusion Criteria:\n\n1. Patients aged 18 years or older with nasal obstruction (NO).\n2. Patients scheduled for surgery: septoplasty ± turbinoplasty ± rhinoplasty for nasal obstruction.\n3. Patients who have undergone a preoperative rhinomanometry assessment.\n4. Patients consented to participation\n\nExclusion Criteria:\n\n1. Nasal polyps.\n2. Chronic edematous-purulent rhinosinusitis (e.g., cystic fibrosis).\n3. Crusting rhinosinusitis (e.g., sarcoidosis, granulomatosis with polyangiitis \\[Wegener's\\]).\n4. Current or previously treated nasal or sinus tumors, or patients undergoing tumor work-up",{"count":57,"type":21},200,"OBSERVATIONAL","Nasal obstruction (NO) affects \\~30% of the population and is a very common reason for consultation in otorhinolaryngology (ORL). In the majority of cases, the origin is inflammatory (allergic rhinitis and chronic rhinosinusitis) while in a minority of cases, the origin is structural, including septal deviation and inferior turbinate hypertrophy.\n\nNO significantly impairs patients' quality of life (QoL) and olfactory performance and also represents a contributing factor and comorbidity in asthma and obstructive sleep apnea syndrome. Several questionnaires for assessing QoL are available and routinely used to evaluate the impact of NO on patients : VAS, NOSE score, SNOT-22, and RhinoQOL score.\n\nSeveral objective functional methods for assessing NO have been described : acoustic rhinometry, nasal peak inspiratory flow, and active rhinomanometry. Rhinomanometry is a simple, non-invasive functional assessment method that allows for objective and quantitative analysis of nasal airway patency, thereby complementing the clinical and imaging evaluation of NO.\n\nIt has been recommended for the diagnosis of NO in cases of chronic rhinitis and chronic rhinosinusitis with nasal polyposis. Rhinomanometry comprises anterior active (AAR), posterior, and per-nasal rhinomanometry. AAR is the most commonly used method and is the only technique routinely available to clinicians. AAR provides precise information regarding the presence of nasal resistance responsible for NO. However, it should not be used as a standalone diagnostic tool due to its poor correlation with QoL questionnaires such as VAS and NOSE.\n\nWhether used alone or in combination with nasal decongestants, AAR provides a high predictive value for the outcomes of septoplasty and laser-assisted turbinoplasty.\n\nWhen surgery is indicated, its performance depends on:\n\n* type of obstruction or anatomical abnormality identified on clinical examination and\u002For computed tomography and\u002For AAR;\n* patient's symptoms and impairment of QoL NOSE and SNOT-22;\n* failure of a well-conducted first-line medical nasal treatment. Thus, in cases of septal deviation, septoplasty is performed; in cases of inferior turbinate mucosal hypertrophy with failure of medical treatment, turbinoplasty is performed; and in cases of mixed lesions, septo-turbinoplasty is performed.\n\nHowever, the concordance rate between the surgical technique indicated by clinical examination and computed tomography and the indications suggested by AAR is only 48.5%.",[61],"Nasal Obstruction",{"date":38,"type":39},{"date":64,"type":39},"2026-01-27",{"date":66,"type":21},"2028-03",{"name":45,"class":46},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":18,"enrollmentInfo":77,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100620281","injury-incidence-severity-and-burden-in-elite-youth-rugby-players-100620281","NCT07355582","Injury Incidence, Severity and Burden in Elite Youth Rugby Players","Injury Incidence, Severity and Burden Over Two Consecutive Seasons in French Elite Youth Rugby Players of Rugby Club Toulonnais","RUBYS","Inclusion Criteria:\n\n* Licensed players (boys or girls) in the RCT Association program from U14 category onwards\n* Players presenting at least one injury requiring medical consultation between 01\u002F08\u002F2024 and 30\u002F06\u002F2026\n\nExclusion Criteria:\n\n* Opposition from participant or parents to participate in the research\n* Players not under medical responsibility of the RCT Association","13 Years",{"count":78,"type":21},400,"Observational cohort study, with a closed, both retrospective and prospective design, aiming to describe the incidence, severity, and burden of injuries among male and female players enrolled in the Rugby Club Toulonnais (RCT) Association program (U14 to U18 categories) over two consecutive seasons (2024-2025 and 2025-2026), based on routinely collected medical data recorded in the Askamon software.\n\nYouth male and female players registered with the RCT Association program, starting from the U14 category, and enrolled in partner school structures within the Toulon Metropolitan area. These players benefit from an integrated academic and athletic support program.\n\nInclusion criteria: male or female players licensed with the RCT Association from the U14 category and above; under the medical supervision of the RCT Association; having sustained at least one injury requiring a medical consultation between August 1, 2024, and June 30, 2026; non-opposition from the participant and\u002For their legal guardians after being informed about the study.\n\nExclusion criteria: opposition from the participant or their parents\u002Flegal guardians to the use of personal data for research purposes; players not under the medical responsibility of the RCT Association.\n\nEnrollment (estimated): approximately 200 licensed players per season, with an estimated 400 injuries per season, and exhaustive inclusion of all injured players from the active registry over two seasons.",[81],"Rugby-related Injuries",[83,84,85,86,87],"Injury","Sport Injury","Sport prevention","Rugby","Injury incidence",{"date":38,"type":39},{"date":90,"type":39},"2025-12-18",{"date":92,"type":21},"2026-06-30",{"name":45,"class":46},2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":47},"100614722","prevalence-of-obstructive-sleep-apnea-in-patients-with-peripheral-arterial-occlusive-disease-100614722","NCT07283289","Prevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease","Prospective Observational Cohort Study on the Prevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease","OSAPAD","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients with a confirmed diagnosis of PAOD, seen either during hospitalization or in an outpatient vascular medicine consultation. Inclusion is permitted regardless of the disease stage (according to the Leriche and Fontaine classification) or prior surgical intervention.\n3. No objection to the use of their pseudonymised medical data\n4. Polygraphy scheduled as part of routine care within one month.\n\nExclusion Criteria:\n\n1. Inability to perform the Ankle-Brachial Index (ABI) or sleep polygraphy due to physical or cognitive constraints (e.g., severe dementia, limb malformation, etc.).\n2. History of OSAS diagnosis confirmed by polygraphy, and currently receiving nocturnal treatment (e.g., Continuous Positive Airway Pressure - CPAP)",{"count":104,"type":21},295,"Obstructive sleep apnea syndrome (OSAS) is characterized by partial (hypopnea) or complete (apnea) obstruction of the upper airways, leading to intermittent hypoxemia and sleep fragmentation. Peripheral arterial occlusive disease (PAOD) is a chronic condition defined by the narrowing or occlusion of arteries in the lower limbs, often resulting in ischemia of downstream tissues. This disease is a common complication of atherosclerosis and affects approximately 1.2% of the general French population.\n\nOSAS is a well-established risk factor for atherosclerotic disease, particularly for coronary and neurovascular events. Although a relationship between OSAS and PAOD has been investigated in recent years, the link has not been definitively established and requires further study. Therefore, this preliminary cohort study aims to observe the prevalence of OSAS among patients diagnosed with PAOD, regardless of the disease stage.",[107],"Peripheral Artery Disease",[109,110,111,112,113],"Obstructive Sleep Apnea Syndrome","Polygraphy","Diagnosis","Prevalence","Peripheral Arterial Occlusive Disease",{"date":38,"type":39},{"date":116,"type":39},"2025-11-05",{"date":118,"type":21},"2026-11",{"name":45,"class":46},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":127,"sex":17,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":94},"100593944","reference-values-for-knee-rotational-amplitudes-in-a-population-of-athletes-100593944","NCT07013019","Reference Values for Knee Rotational Amplitudes in a Population of Athletes","PRELAX","Inclusion Criteria:\n\n1. Athletes with healthy knees, men and women ;\n2. Age greater than or equal to 15 years;\n3. Competitive pivot sports.\n\nExclusion Criteria:\n\n1. History of ligament, meniscus, cartilage or bone lesions in the knee ;\n2. Pain, stiffness or instability in the knee at the time of inclusion;\n3. Knee surgery, including ligament reconstruction;\n4. Systemic diseases or medical conditions that may affect the musculoskeletal system;\n5. Opposition of the participant and\u002For his\u002Fher legal representative in the case of a minor participant;\n6. Participant under protective supervision.",true,"15 Years",{"count":130,"type":21},482,"Rupture of the anterior cruciate ligament (ACL) is a frequent and disabling injury in pivot sports, leading to knee laxity and instability, reduced performance and an increased risk of early osteoarthritis. The risk is 2 to 8 times higher in women, linked to greater ligament laxity and a different quadriceps\u002Fhamstring muscle ratio post-puberty.\n\nTo assess knee laxity and the degree of ligament damage, anterior tibial translation (of the tibia below the femur) is usually measured. This translation is symmetrical and varies between 3 and 10 mm depending on the individual (natural laxity). It is increased in cases of ACL damage.\n\nMeasuring tibial rotation is also of interest in this context. Studies show that the ACL plays a crucial role in controlling internal and external tibial rotation, especially during low-flexion movements (between 10° and 30°). ACL rupture also significantly increases this rotation, aggravating knee instability.\n\nIt therefore seems important to study both tibial rotation and tibial translation to assess knee laxity. Combining these two measurements seems to improve diagnostic accuracy. This multifactorial approach could provide additional information on biomechanical abnormalities and predisposition to injury. The use of biomechanical data, such as normative values for tibial rotation, is fundamental to prevention, and preventive exercise programs reduce the risk of rupture4. Defining these norms would help identify athletes at risk and personalize preventive strategies.\n\nInstrumented assessment of laxity, using devices such as the DYNEELAX dynamic arthrometer, enables precise quantification of tibial rotation and anterior tibial translation under controlled loads. Its reliability has been proven5 and its use has been mastered at Toulon (\"Unité de Médicine et Traumatologie du Sport\") and Brest (Centre de Médecine du Sport\"). It will be used in the PRELAX project to define normative tibial rotation values.",[133],"Knee Ligament Injury",[135,83,136,137,138],"Anterior cruciate ligament","Laxity","Pivot sport","Dynamic arthrometer",{"date":38,"type":39},{"date":141,"type":39},"2025-06-06",{"date":143,"type":21},"2026-06",{"name":45,"class":46},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":47},"100595848","monitoring-of-patient-physiological-parameters-in-real-life-using-oxyflex-biosensors-versus-standard-monitoring-100595848","NCT07037784","Monitoring of Patient Physiological Parameters in Real Life Using OXYFLEX® Biosensors Versus Standard Monitoring","Monitoring of Physiological Parameters in Real Life in Patients Managed in Anesthesia, Rehabilitation\u002FIntensive Care Unit and Traumatology Services, Using OXYFLEX® Biosensors Versus Standard Monitoring","OXYVIVO","Inclusion Criteria:\n\n* Adult patient (≥ 18 years old);\n* Patient taken care of :\n* in severe traum pathway in the emergency services department\n* or in the operating room for a general anesthesia procedur or locoregional anesthesia planned for a surgical duration grater than 2 hours\n* or admitted to intesive care\u002F general intensive care units.\n\nExclusion Criteria:\n\n* Opposition from the patient or their family to participate in the research ;\n* Pregnant, parturient or breastfeeding woman ;\n* Patient under judical protection (guardianship, curatorship …) or legal safeguarding ;\n* Inability to wear the headband and the sensor (in particular : intracranial neurosurgery, othorhinolaryngology or maxillofacial surgery, debilitating trauma to the head or face …) ;\n* Any other reason that, in the investigator's opinion, could interfere with the evaluation of the study objectives.",{"count":154,"type":21},102,[24],"The purpose of this study is to use the OXYFLEX® device in real care conditions during the hospital management of a population of patients from various hospital services. These services include patients from the severe trauma pathway, intensive care, the polyvalent intensive care unit, and the operating room. The objective is to assess the reliability of the data collected by the OXYFLEX® biosensor compared to those obtained from standard monitoring used in these different services and conditions.",[158],"Physiological Parameters",[160,161,162,163,164,165],"biosensor","early warning score","real care conditions","traumatology","anesthesia","intensive care","NOT_YET_RECRUITING",{"date":38,"type":39},{"date":143,"type":21},{"date":170,"type":21},"2026-12",{"name":45,"class":46},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":94},"100599675","3d-printers-for-autonomy-in-the-care-of-inpatients-in-continuing-and-rehabilitation-care-100599675","NCT07087574","3D Printers for Autonomy in the Care of Inpatients in Continuing and Rehabilitation Care","AUTARI-3D","Inclusion Criteria:\n\n1. Patient hospitalized in a Continuing Care and Rehabilitation department ;\n2. Patient suffering from a neurodegenerative disease (Mini Mental Test score \\> 15);\n3. Age ≥ 18 years;\n4. Patient with a score ≥ 3 on the \"Eating\" criterion of the Katz scale (corresponding to the need for at least partial assistance with meals).\n\nExclusion Criteria:\n\n1. Opposition of the patient or his relatives to participating in the research ;\n2. Patient unable to use hands to eat (amputation, paralysis, etc.);\n3. Patient under court protection;\n4. Pregnant, parturient or breast-feeding woman;\n5. Any other reason which, in the opinion of the investigator, could interfere with the evaluation of the study objectives.",{"count":180,"type":21},75,[24],"Patients hospitalized in Continuing and Rehabilitation Care Units (CRCU) are for the most part elderly people suffering from neurodegenerative diseases, requiring individual, personalized rehabilitation care.\n\nSome of these patients require ergotherapy to help them regain functional ability in everyday activities. The ergotherapist organizes therapeutic activities tailored to patients' needs, with a view to optimizing their level of autonomy.\n\nLoss of autonomy is closely linked to nutritional status, which often tends towards malnutrition in patients admitted to CRCU, with deleterious consequences for the elderly. The use of technical aids to facilitate meal-taking could be a way of alleviating undernutrition. A technical aid is defined as a material aid that enables elderly or disabled people to compensate for a limitation in activity.\n\nThe investigators are interested in the use of adapted cutlery, as patients often find it difficult to eat on their own, being unable to grip their cutlery correctly. Commercially adapted cutlery exists, but it is expensive and difficult to use because it is not adapted to each patient (standard size) and is too heavy. What's more, the investigators observe that their use does not necessarily improve the patient's degree of dependence, generally measured by the Katz scale.\n\nThe idea of the team of ergotherapist is to offer ergonomic cutlery handles with diameters adapted to patients' degree of prehension. They offer handles with diameters of 25 mm, 30 mm, 35 mm and 40 mm. The diameter is customized according to the hand's flexion capacity, as assessed by a joint and functional assessment. What's original about these technical aids is that they are designed from thermoformable materials with the help of a 3 Dimension printer and Computer-Aided Design and Manufacturing software, in partnership with the Fablab (Fabrication laboratory) in Toulon and the Hyères media library. They have the added advantage of being lightweight and inexpensive.",[184],"Neuro-Degenerative Disease",{"date":38,"type":39},{"date":187,"type":39},"2026-03-30",{"date":189,"type":21},"2027-10",{"name":45,"class":46},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":127,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":47},"100587277","moral-injury-in-french-healthcare-workers-100587277","NCT06926296","Moral Injury in French Healthcare Workers","MI-PRO","Inclusion Criteria:\n\n* Healthcare workers\n\nExclusion Criteria:\n\n* Absence of consent",{"count":199,"type":21},3073,[24],"Healthcare professionals are facing an escalating crisis, with burnout rates ranging between 40% and 60% and a growing intention to leave the profession, affecting one in five physicians and one in four nurses in the coming years. While current interventions focused on individual resilience, such as mindfulness, peer support, and workload management, have been promoted as solutions, they have failed to bring about systemic improvements. This raises the question of whether other factors, such as Moral Injury, play a key role in this crisis. Moral Injury is an emerging concept that highlights the profound misalignment between healthcare workers' professional values and the reality of their practice, often exacerbated by organizational and economic constraints.\n\nThe objective of this study is to describe the manifestations of Moral Injury among healthcare professionals in France. By establishing the first large-scale assessment of Moral Injury among healthcare professionals in France, this study aims to identify key organizational and personal risk factors contributing to this phenomenon. The use of Structural Equation Modeling will help build a robust theoretical model that clarifies the underlying mechanisms of Moral Injury and its interactions with broader health issues. The findings will support the development of targeted interventions focused on systemic organizational changes to improve healthcare workers' well-being and guide public health policies.",[203],"Moral Injury",[205,206,207,208,209,210],"Moral injury","Burnout","Depression","Anxiety","Healthcare workers","Health services research",{"date":38,"type":39},{"date":213,"type":39},"2025-11-19",{"date":170,"type":21},{"name":45,"class":46},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":47},"100585648","eccentric-or-concentric-contralateral-training-in-rehabilitation-after-shoulder-surgery-with-elbow-immobilization-100585648","NCT06905093","Eccentric or Concentric Contralateral Training in Rehabilitation After Shoulder Surgery With Elbow Immobilization","EXC-IMMO","Inclusion Criteria:\n\n* Adult patient (≥ 18 years old) undergoing shoulder surgery (i.e., Bankart procedure, rotator cuff repair, arthroplasty)\n* With an indication for immobilization, expected to last 4 to 6 weeks\n* Free from any neurological pathology\n* Having provided their informed consent before any participation in the research\n\nExclusion Criteria:\n\n* Having a medical contraindication to the practice of physical and sports activities\n* Presenting an expected modification of their physical activity of the non-immobilized limb\n* Having suffered an injury to the upper limbs in the last 6 months\n* Having already undergone surgery on the upper limbs\n* Pregnant, parturient, and breastfeeding women\n* Presenting a medically established alteration of their cognitive functions\n* Subject under guardianship, curatorship, family empowerment, or judicial safeguard\n* Not affiliated or beneficiary of health insurance coverage\n* Any other reason that, in the investigator's opinion, could interfere with the evaluation of the study objectives",{"count":224,"type":21},42,[24],"This clinical study investigates whether contralateral training (exercising the non-immobilized arm) can help preserve muscle strength and mass in patients recovering from shoulder surgery with elbow immobilization. Immobilization is often necessary to prevent further injury, but it can lead to significant muscle loss and reduced strength, delaying recovery and increasing healthcare costs. Recent studies suggest that training the non-immobilized arm may help maintain muscle function in the immobilized arm, particularly when using eccentric exercises (where muscles lengthen under tension). This study aims to compare the effects of eccentric and concentric (shortening) contralateral training versus standard care (no training) in patients undergoing shoulder surgery.\n\nThe study involves 4 visits: pre-surgery assessments, a 4-6 weeks' immobilization period with or without training, and follow-ups at the end of immobilization, 6 weeks' post-immobilization, and 17 weeks' post-immobilization. Participants will be randomly assigned to one of three groups: a control group receiving standard care, a group performing eccentric training, or a group performing concentric training. Muscle strength, mass, and function will be measured using tests such as isometric strength, ultrasound imaging, and functional scores.\n\nThe hypothesis is that eccentric contralateral training will better preserve neuromuscular function and muscle mass in the immobilized arm compared to both standard care and concentric training. This could lead to faster recovery and improved outcomes for patients. The study will provide valuable insights into optimizing rehabilitation strategies for patients recovering from shoulder surgery.",[228],"Shoulder Surgery",[230,231,232,233,234,235],"Cross-education","Contralateral training","Eccentric training","Concentric training","Immobilization","Rehabilitation",{"date":38,"type":39},{"date":238,"type":39},"2025-12-02",{"date":189,"type":21},{"name":45,"class":46},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":47},"100584792","acute-intra-ocular-pressure-monitoring-after-aflibercept-8mg007ml-100584792","NCT06893965","Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg\u002F0.07mL","Intra Ocular Pressure Monitoring After Intravitreal Injection of Aflibercept 8mg\u002F0.07mL","AFLIPIO","Inclusion Criteria:\n\n* Patient aged 18 or over;\n* Patient with an indication for Aflibercept 8mg\u002F0.07mL (EYLEA 8mg)\n* Naive or switched patient, i.e. so-called suboptimal responder to anti-VEGF with high injection frequencies\n* Patient with rights to social security\n* Having given free and informed consent before any participation in research.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Patient under legal protection (guardianship, curatorship, etc.) or legal protection\n* Patient with significant astigmatism distorting the IOP values in applanation\n* Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the study objectives",{"count":250,"type":21},100,[24],"In just a few years, intravitreal injections have become a standard method of administration for certain retinal deseases (age-related macular degeneration \\[AMD\\], diabetic edematous maculopathy or retinal vein occlusion \\[RVO\\]). Thus, vascular endothelial growth factor (anti-VEGF) inhibitors are injected repetitively, every 4 to 6 weeks, in some patients in order to treat such pathologies.\n\nIt is established that each of these IVTs has repercussions on the intraocular pressure (IOP) of patients. They immediately present with an intraocular pressure spike (IOP reaching nearly 50mmHg) for a duration of a few minutes (between 15 and 30 minutes) when the injected volume is 0.05mL, which is currently used.\n\nIn order to reduce the frequency of injections in patients, higher concentrations of active ingredients with anti-VEGF properties will arrive on the market with higher injection volumes of up to 0.07mL (marketing of Aflibercept 8mg\u002F0.07ml in France since 01\u002F06\u002F2025. As IOP spikes are linked to the volume injected, the repercussions of such volumes could probably be greater and require additional actions. Indeed, currently the volumes used (0.05mL) rarely lead to complications such as transient blindness secondary to ocular hypertonia. In this case, an anterior chamber puncture may be necessary.\n\nTo date, the impact on IOP of the 0.07mL injection has not yet been evaluated in the short and long term. Indeed, the repetition of IVT leads to a repetition of IOP peaks of around 50mmHg in the same patient. Some studies have analyzed the anatomical repercussions on the optic nerve of these peaks and have noted a reduction in the thickness of the peripapillary nerve fibers (RNFL for Retinal Nerve Fiber Layer) in Optical Coherence Tomography (OCT for Optical Coherence Tomography) after the 3 monthly IVTs recommended for the induction phase of treatment. But other studies have not found a significant drop in RNFL after several years of regular treatment with IVT. The studies were all carried out with volumes of 0.05mL and the repercussions with a volume of 0.07mL are therefore not reported in the literature.\n\nThe AFLIPIO study aims to study the short-term pressure profile after performing an IVT of Aflibercept, at a volume of 0.07mL, and to evaluate the longer-term anatomical repercussions (12 months) on the head of the optic nerve when repeating IVT of Aflibercept, at a volume of 0.07mL.",[254],"Macular Diseases",[256,257,258,259,260],"Diabetic Macula Edema","Intravitreal injection","Anti-VEGF","Aflibercept","Wet age-related macular degeneration (AMD)",{"date":38,"type":39},{"date":263,"type":39},"2025-07-08",{"date":265,"type":21},"2029-07",{"name":45,"class":46},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":294},"100579084","tourniquet-vs-dual-flow-arthroscopy-sheath-in-anterior-cruciate-ligament-acl-reconstruction-100579084","NCT06819696","Tourniquet vs. Dual-flow Arthroscopy Sheath in Anterior Cruciate Ligament (ACL) Reconstruction","A Prospective, Randomized Controlled Study Comparing Tourniquet Use Versus a Dual-flow Arthroscopy Sheath in Anterior Cruciate Ligament (ACL) Reconstruction Surgery.","RELICA","Inclusion Criteria:\n\n* Primary ACL reconstruction\n* Age 18 years or older\n* Provided informed consent prior to study participation\n* Affiliated to or beneficiary of a social security regimen\n\nExclusion Criteria:\n\n* Multi-ligamentous surgery\n* Revision ACL surgery\n* Presence of a meniscal and\u002For chondral lesion not allowing immediate weight-bearing postoperatively\n* Bleeding disorder\n* Pregnant, parturient or breastfeeding women\n* Patient under legal guardianship\n* Any other reason which, in the opinion of the investigator, could interfere with the evaluation of the objectives of the study objectives",{"count":276,"type":21},128,[24],"This is a prospective randomized study comparing tourniquet use versus a dual-flow arthroscopy sheath in Anterior Cruciate Ligament (ACL) reconstruction surgery.\n\nThe ACL is largely responsible for knee stability and contributes to central pivot with the posterior cruciate ligament. ACL rupture is associated with a violent twisting motion of the knee, which is usually irreparable without surgical intervention.\n\nACL reconstruction via arthroscopy is the gold standard treatment for young, active patients with knee instability. Reconstruction is commonly performed using a thigh tourniquet to improve intraoperative visibility, reduce bleeding, and shorten procedure time. However, numerous studies associate tourniquet use with an increased risk of postoperative complications such as increased pain, muscle injury, postoperative bleeding, and deep vein thrombosis. Therefore, it seems relevant to conduct further investigations into the benefits of new methods to replace tourniquet. In this context, the dual-flow arthroscopy sheath could improve postoperative recovery after ACL reconstruction and could limit the risk of complications, thus improving ambulatory care for patients.\n\nThis study propose to compare two groups of patients undergoing ACL reconstruction: those operated on with a tourniquet versus those operated on using the dual-flow arthroscopy sheath.",[280],"Anterior Cruciate Ligament Reconstruction",[282,283,284,285,286,287],"Anterior Cruciate Ligament","Arthroscopy","Dual-flow arthroscopy sheath","Tourniquet","pain","Surgery",{"date":38,"type":39},{"date":290,"type":39},"2025-05-12",{"date":292,"type":21},"2028-04",{"name":45,"class":46},3,{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":94},"100560801","evaluation-of-a-collaborative-mental-health-care-system-100560801","NCT06581874","Evaluation of a Collaborative Mental Health Care System","MED@PSY","Inclusion Criteria:\n\n* Patient ≥ 18 years ;\n* Patient presenting to the Centre hospitalier de Toulon La Seyne sur Mer emergency department, with or without referral, and receiving psychiatric advice with discharge without hospitalization after clinical assessment (Group 1) or patients referred for psychiatric consultation via the Med@psy system (Group 2).\n* Patient with indication for outpatient follow-up\n* Patient with open social security rights\n\nExclusion Criteria:\n\n* Patient's refusal to take part in research ;\n* Patient currently being followed by a psychiatrist. Psychiatric follow-up is defined as at least one consultation with a psychiatrist in the last 3 months, outside an unscheduled care consultation or in an emergency department;\n* Patients referred for a suicide attempt, violent or non-violent, serious or non-serious;\n* Patients without a declared general practioner;\n* Patients already included in the study;\n* Patients who do not speak French;\n* Patients under judicial protection (guardianship, curatorship, etc.) or safeguard of justice;\n* Patient under compulsory care, under a care order or deprived of liberty.\n* Any other reason which, in the investigator's opinion, could interfere",{"count":303,"type":21},418,[24],"In the absence of easy access to second-line ambulatory care, the number of 'inappropriate' psychiatric emergency visits is increasing, with emergency departments becoming the gateway to mental health care.\n\nThis is the context in which the 'med@psy' system was set up in the Toulon-Provence-Mediterranean metropolitan area by a private psychiatrist. It facilitates access to psychiatric second referral for General Practitioners (GPs) by pooling the 48-hour supply of psychiatric consultations in real time. It is assumed that this system will facilitate access to outpatient psychiatric care and help to optimize the organisation of patient care and follow-up. The aim of this study is to evaluate the med@psy system in the care pathway for patients with psychiatric disorders.\n\nThis study main objective is to compare the proportion of patients with a psychiatric disorder who will receive outpatient follow-up 1 month after a visit to a psychiatric emergency department without hospitalization (Group 1) versus 1 month after a consultation with a psychiatrist within 48 hours via the med@psy system (Group 2).",[307],"Psychiatric Adults Patients",[309,310,311,312,313],"psychiatry","outpatient follow-up","emergency","ehealth","collaborative care",{"date":38,"type":39},{"date":316,"type":39},"2025-03-03",{"date":318,"type":21},"2027-06",{"name":45,"class":46},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":344,"locationsCount":47},"100557446","evaluation-of-the-care-pathway-offered-by-the-chronic-disease-unit-to-obese-patients-100557446","NCT06538220","Evaluation of the Care Pathway Offered by the \"Chronic Disease Unit\" to Obese Patients","Evaluation of the Care Pathway Offered by the \"Chonic Disease Unit\" to Obese Patients","EVAMMACH","Inclusion Criteria:\n\n1. Patient identified by the network or referred by a healthcare professional,\n2. Patient aged 18 or over,\n3. Patient suffering from obesity defined by a BMI ≥ 30,\n4. Patient who understands and speaks French.\n\nExclusion Criteria:\n\n1. Opposition of the patient to participation in the study,\n2. Pregnant, parturient or breast-feeding woman,\n3. Patient undergoing bariatric surgery,\n4. Patient under judicial protection (guardianship, curatorship, etc.) or safeguard of justice,\n5. Patients with unstable psychiatric disorders,\n6. Patients on neuroleptics,\n7. Any other reason which in the opinion of the investigator, could interfere with the evaluation of the study objectives.",{"count":329,"type":21},133,[24],"Obesity is a chronic and progressive disease medically defined as an increase in body fat, with consequences for physical, psychological and social well-being. With an estimated prevalence of 17% in France, obesity and its management remain a major public health issue. Projections by the World Health Organisation (WHO) show that the prevalence of non-communicable diseases, including obesity, is set to rise again by 2030 in all European countries.\n\nTo support patients and prevent obesity development, the French National Authority for Health (HAS) advocates change in practices and places patient education at the heart of care. The management of chronic diseases such as obesity must be offered on a long-term basis, adapting to complications onset, and patients must become active players in their treatment and the proposed care pathway. However, our experience shows that patients have difficulty finding their way around a care pathway and identifying the medical or paramedical resources that could help them to set their health goals and initiate change.\n\nThat's why the Var region has developed the \"Chronic Disease Unit\", which offers coordinated, adapted and individualised care pathways for patients suffering from chronic illnesses, including obesity; therapeutic education and the psychosocial dimension are at the heart of the Chronic Disease Unit approach. Depending on their psychosocial skills, each patient will be encouraged to develop skills at their own pace, but also to become autonomous in managing their illness and taking part in the healthcare decisions about them. To be autonomous, a patient must not only know what to do, but also feel able to do it, i.e. develop a sense of self-efficacy. When they have the necessary skills and believe in their abilities, patients are more likely to adopt health-promoting behaviours. While obesity generally seems to be linked to a low self-efficacy, the self-efficacy appears to be involved in weight management quality, commitment to a programme and the weight loss extent that results.\n\nThe aim of EVAMMACH study is to evaluate if the Chronic Disease Unit care pathway could promote obese patients' sense of self-efficacy and meet their expectations.",[333],"Obesity",[335,336,337,333,338,339],"Care pathway","Self-efficacy","Patient education","Interdisciplinary","Self mangement",{"date":38,"type":39},{"date":342,"type":39},"2024-10-16",{"date":292,"type":21},{"name":45,"class":46},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":373},"100558524","phase-2-phase-ii-efficacy-study-of-repotrectinib-in-frail-andor-elderly-patients-with-ros1-rearranged-advanced-nsclc-100558524","NCT06552234","Phase II Efficacy Study of Repotrectinib in Frail and\u002For Elderly Patients With ROS1-rearranged Advanced NSCLC","Open-label Phase II Efficacy Study of Repotrectinib in Frail (PS ≥2) and\u002For Elderly Patients With ROS1-rearranged Advanced NSCLC","REPOROS","Inclusion Criteria:\n\n* Eligible patients are defined as patients with\n\n  * Eastern Cooperative Oncology Group (ECOG) PS ≥ 2 at the time of inclusion and\u002For\n  * Age ≥ 70 years\n* Age ≥ 18 years\n* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC harboring an ROS1 gene rearrangement as by any nucleic acid-based diagnostic testing method (e.g., next-generation sequencing \\[NGS\\], Sanger sequencing, reverse transcription-polymerase chain reaction), Break-apart fluorescence in situ hybridization (FISH) or Immunohistochemistry (IHC) (confirmed by NGS or qPCR test).\n* Willing and able to provide written institutional review board (IRB)\u002Finstitutional ethics committee-approved Informed Consent.\n* At least 1 measurable target lesion according to RECIST (v1.1). CNS-only measurable disease as defined by RECIST (v1.1) is allowed.\n* Prior cytotoxic chemotherapy for advanced or metastatic disease is allowed. At the time of starting treatment with repotrectinib, at least 14 days or 5 half-lives (whichever is shorter) must have elapsed after discontinuation of prior cytotoxic chemotherapy (or at least 42 days for prior nitrosoureas, mitomycin C, and liposomal doxorubicin) and all side effects from prior treatments must have resolved to grade ≤ \\_1 (CTCAE Version 5.0 with the exception of alopecia.\n* Prior immunotherapy (e.g., anti-PD-1, anti-PDL1, anti-TIM3, anti-OX40) is allowed. At the time of starting treatment with repotrectinib, at least 14 days must have elapsed after discontinuation of prior immunotherapy treatment and all immune-related side effects from prior treatments must have resolved to grade ≤ \\_1.\n* No prior ROS1 TKI is allowed for the TKI naïve cohort.\n* Prior ROS1 TKI is allowed for the TKI pretreated cohort (max 30% of patients). At least 7 days or 5 half-lives (whichever is shorter) must have elapsed since completion of treatment with the last ROS1i prior to starting treatment with repotrectinib for subjects enrolling into the TKI-pretreated expansion cohorts. All side effects from prior treatments with ROS1i must have resolved to grade ≤ \\_1 prior to starting treatment with repotrectinib.\n\n  * Prior ROS1i allowed include crizotinib, ceritinib, lorlatinib, brigatinib, entrectinib, ensartinib, cabozantinib.\n* Subjects with symptomatic CNS metastases and\u002For asymptomatic leptomeningeal carcinomatosis are eligible.\n* Life expectancy ≥3 months\n* Subject affiliated to an appropriate social security system\n* Adequate hematologic and end-organ function, defined by the following laboratory\n\n  * ANC ≥ 1500 \u002Fmm3 without granulocyte colony-stimulating factor support\n  * Lymphocyte count ≥ 500\u002Fmm3\n  * Platelet count ≥ 100,000\u002Fmm3 without transfusion\n  * Hemoglobin ≥ 9.0 g\u002FdL. Patients may be transfused to meet this criterion.\n  * INR or aPTT ≤ 1.5, upper limit of normal (ULN)\n  * This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be receiving a stable dose.\n  * ASAT, ALAT, and alkaline phosphatase ≤ 2.5xULN, with the following exceptions:\n  * Patients with documented liver metastases: ASAT and\u002For ALAT ≤ 5xULN\n  * Patients with documented liver or bone metastases: alkaline phosphatase \\\u003C 5xULN\n  * Serum bilirubin ≤1.25xULN\n  * Patients with known Gilbert disease who have serum bilirubin level ≤ 3xULN may be enrolled.\n  * Calculated creatinine clearance (CRCL) ≥ 45 mL\u002Fmin\n* Adequate method of contraception during the treatment period\n\n  * For Females:\n\nAll women of childbearing potential (WOCBP) must agree to avoid pregnancy during the study and must use a highly effective method of contraception during study treatment with repotrectinib and for at least 2 months following the final dose.\n\nHighly effective contraceptive methods consist of prior sterilization, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), injectable or implantable contraceptives and abstinence.\n\nHormonal contraception must begin 7 days prior to the first dose of study treatment.\n\nDue to a potential loss of effectiveness of hormonal contraceptives caused by interaction with study intervention, if WOCBP use hormonal contraceptives (including oral hormonal contraceptives), they must use either another form of non-hormonal highly effective contraception or a reliable barrier method.\n\nFemale subjects must refrain from egg donation from screening through at least 2 months after the last dose of study drug.\n\n* For Males:\n\nMale participants with WOCBP partners must use latex condoms during treatment with repotrectinib and for 4 months following the final dose even if the participant has undergone a successful vasectomy or if the partner is pregnant or breastfeeding.\n\nMale subjects must refrain from sperm donation from screening through at least 4 months after the last dose of study drug\n\nExclusion Criteria:\n\n* Malignancies other than NSCLC within 2 years prior to inclusion, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS ≥ 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\n* Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[HBcAb\\] and absence of HBsAg) are eligible only if they are negative for HBV DNA. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA.\n* Active tuberculosis\n* Severe infections within 2 weeks prior to inclusion, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to inclusion, unstable arrhythmias, or unstable angina\n* Major surgical procedure other than for diagnosis within 28 days prior to inclusion or anticipation of need for a major surgical procedure during the course of the study\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.\n* Patients with illnesses or conditions that interfere with their capacity to understand follow and\u002For comply with study procedures.\n* Concurrent participation in any therapeutic clinical trial\n* Patient deprived of liberty or placed under the authority of a tutor or a curator\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol",{"count":354,"type":21},30,[356],"PHASE2","ROS1 rearrangements are rare, accounting for only 1-2% of NSCLC cases, but have been associated with response to ROS1 inhibitors, such as crizotinib and entrectinib. However, many patients develop resistance to the tyrosine-kinase inhibitors (TKIs), creating a need for new treatments.\n\nRepotrectinib is a new-generation TKI designed against ROS1 or NTRK rearranged malignancies (Drilon 2018). Early phase clinical data support activity of repotrectinib in patients with NSCLC harboring such gene rearrangements (TRIDENT-1 study), but there are limited evidence in frail populations, such as poor performance status patients and\u002For elderly patients, who are classically excluded from clinical trials or underrepresented.\n\nThe present study aims to assess the activity and tolerability of repotrectinib in frail (PS ≥2) and\u002For elderly patients with ROS1-rearranged advanced NSCLC.",[359,360],"NSCLC Stage IV","NSCLC, Stage III",[362,363,364,365,366],"tyrosine-kinase inhibitors","Frail patients","Elderly patients","ROS1 rearrangements","resistance",{"date":38,"type":39},{"date":369,"type":39},"2024-10-01",{"date":371,"type":21},"2031-09",{"name":45,"class":46},20,{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":47},"100552447","neuroprotective-effect-of-remote-ischemic-post-conditioning-in-out-of-hospital-cardiac-arrest-100552447","NCT06473207","Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest","Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest : a Randomized Open Label Controlled Trial","RIPOST-CA","Inclusion Criteria:\n\n* Out-of-hospital cardiac arrest with stable return of spontaneous circulation (ROSC \\> 20 minutes)\n* Patient receiving invasive mechanical ventilation for coma (Glasgow score \\\u003C 8)\n* Availability of a lower limb without intravenous infusion or tension cuff positioned on it\n* Randomization and application of the first session of the tested procedure within 4 hours after ROSC\n* Consent of a next-of-kin or inclusion in emergency procedure\n\nExclusion criteria :\n\n* Age \\\u003C 18 y.o or pregnancy\n* Patient unable to walk without assistance, unable to support himself properly without assistance, bedridden, incontinent and requiring nursing constant attention and care (corresponding to a mRS equal to 4 or 5)\n* Interval between cardiac arrest and ROSC (no flow + low flow) estimated \\> 60 minutes\n* Unwitnessed cardiac arrest with asystole as first rhythm\n* In-hospital cardiac arrest\n* Refractory cardiac arrest (no ROSC considered as stable)\n* Cardiac arrest from traumatic, hemorrhage, stroke or hanging supposed origin\n* Mean arterial pressure \\\u003C 65mmHg persisting despite appropriate vascular filling and vasopressor and\u002For inotropic support\n* Active uncontrolled bleeding\n* Contraindication or not possible to use a pneumatic tourniquet on none of the two lower limbs (amputations, intravenous infusion positioned on both lower limbs, tourniquet size incompatible with patient morphology)\n* Implementation of extracorporeal arteriovenous circulation for refractory cardiac arrest or refractory cardiogenic shock before inclusion\n* Patient already included in this study\n* Inclusion in another interventional study which purpose is to improve prognosis after a cardiac arrest\n* Judicial protection measure\n* Patient without French social security",{"count":383,"type":21},48,[24],"Patients admitted to intensive care unit (ICU) following an out-of-hospital cardiac arrest (OHCA) have a high morbidity and mortality rate, primarily due to ischemia-reperfusion (I\u002FR) syndrome leading to anoxic-ischemic brain injury. Despite current recommended advanced life support therapies, no specific treatment or procedure has yet been shown to improve the neurological outcome of such patients.\n\nRemote ischemic post-conditioning (RIPOST) which usually consists of applying brief and repeated cycles of ischemia alternating with reperfusion by inflating and deflating a blood pressure cuff or a pneumatic tourniquet placed around a limb, is a promising strategy to protect organs against I\u002FR injury, including brain. Regarding cardiac arrest, pre-clinical studies have demonstrated an improvement in neurological outcome in animal subjects treated with RIPOST after cardiopulmonary resuscitation.\n\nThe aim of our study is to demonstrate the benefit of early RIPOST in OHCA patients in reducing neurological injury and organ failure related to I\u002FR syndrome.",[387],"Out-Of-Hospital Cardiac Arrest",[389,390,391,392],"Remote ischemic conditioning","Out-of-hospital cardiac arrest","Neuroprotection","Cardiac arrest",{"date":38,"type":39},{"date":395,"type":39},"2025-01-11",{"date":292,"type":21},{"name":45,"class":46},{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":421,"locationsCount":422},"100545703","dvt-burden-and-the-risk-of-post-thrombotic-syndrome-100545703","NCT06385353","DVT Burden and the Risk of Post-thrombotic Syndrome","Baseline Ultrasound Venous Thrombosis Burden and the Risk of Post-thrombotic Syndrome in Patients With a First Acute Episode of Symptomatic Deep Vein Thrombosis of the Lower Limbs - The \"DVT-Burden\" Project -","DVT-Burden","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients with symptomatic acute deep venous thrombosis of the lower limbs confirmed by ultrasound on the criteria of venous incompressibility and direct image of the thrombus (patients with stable pulmonary embolism associated with a symptomatic deep venous thrombosis can be included)\n3. Affiliates or beneficiaries of a social security scheme.\n\nExclusion Criteria:\n\n1. Pregnant women, women in labour or breastfeeding mothers.\n2. Pulmonary embolism haemodynamically unstable defined by systolic blood pressure \\\u003C 90 mmHg or a drop in systolic blood pressure of at least 40 mmHg during at least 15 min, shock or cardiac arrest.\n3. Asymptomatic venous thrombosis.\n4. Symptomatic venous thrombosis of both lower limbs (patients with bilateral deep venous thrombosis but symptomatic on one side only can be included).\n5. History of ipsilateral or contralateral venous thrombosis of the lower limb.\n6. Fracture or orthopedic surgery of the lower limbs in the last 3 months.\n7. Dependance caused by age or secondary to a chronic affection, going from the inability to stand up or walk alone without help to bed or armchair rest over.\n8. Prophylactic or therapeutic anticoagulant treatment \\> 5 days.\n9. Expected duration of anticoagulant treatment \\\u003C 3 months (all patients must have a minimum treatment of 3 months).\n10. Patient estimated at high risk of bleeding according to investigator clinical judgment (renal, platelet, digestive, hepatic, neurological... origin) .\n11. Indication for interruption of the inferior vena cava or venous recanalisation (endovascular, thrombolysis or surgery).\n12. Refusal or inability to give written informed consent to participate in the study.\n13. Life expectancy \\\u003C 6 months.\n14. Patients under legal protection (guardianship, curatorship, etc.) or safeguard of justice.\n15. Patients taking part in a research project for venous thromboembolism that can interfere with the conduct of DVT-BURDEN research.",{"count":78,"type":21},[24],"Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis (DVT), with major consequences for patient quality of life and cost of management. Identifying patients at high risk of developing PTS could be useful for its prevention and may lead to more appropriate therapeutic strategies to reduce its incidence and severity.\n\nPrognostic tools for predicting risk are very useful for choosing the optimum treatment and improving patient management and are a preliminary step before developing predictive models useful for determining sensitivity to treatment. At present, although several prognostic markers and models have been proposed, it is still difficult to predict who will develop a PTS or a moderate to severe PTS. The development of PTS is multifactorial and depends largely on the extent and severity of venous obstruction which supports the theory of thrombosis burden (DVT-Burden) as a potential prognostic marker for PTS. It therefore seems important to study the association between thrombosis burden and the occurrence of PTS.\n\nThe Venous Volumetric Index or VVI (Ouriel 1999) will be used for quantifying DVT-Burden. The VVI was constructed by calculating the volume from the diameter and length of 14 venous segments from the calf veins to the inferior vena cava. The VVI has been validated for its ability to discriminate between symptomatic and asymptomatic DVT and has shown superior performance to other methods for quantifying DVT.\n\nThis study aim to assess the performance of baseline DVT-burden estimated by the VVI score on ultrasound for predicting the occurrence and the severity of PTS as assessed by the Villalta scale at 6 months.",[410],"Postthrombotic Syndrome",[412,413,414,415,416],"Venous thrombosis","Thrombus burden","Ultrasonography","Thrombus resolution","Post-thrombotic syndrome",{"date":38,"type":39},{"date":419,"type":39},"2024-06-05",{"date":318,"type":21},{"name":45,"class":46},27,{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":47},"100530220","data-clustering-study-with-artificial-intelligence-and-phenotyping-of-patients-with-acute-pulmonary-embolism-100530220","NCT06183944","Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism","Data Clustering Study With Artificial Intelligence and Phenotyping of Patients Who Presented With Acute Pulmonary Embolism","PEPITE","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patient with acute pulmonary embolism in CHITS (hospitalised or not).\n\nExclusion Criteria:\n\n* Sub-segmental pulmonary embolisms ;\n* Patient opposition.",{"count":432,"type":21},2500,"The aim will be to identify clinically relevant phenotypes in patients with acute pulmonary embolism. Hierarchical clustering methods combined with unsupervised learning (machine learning) will be used to obtain groups of patients who are homogeneous at diagnosis. Evaluating their prognosis at 6 months (recurrence or chronic thromboembolic pulmonary hypertension), account the first 3 months of anticoagulant treatment, would provide an aid to medical decision-making.\n\nThis research will include a retrospective and a prospective parts. The retrospective part will include patients who have been admitted to CHITS for acute pulmonary embolism since 2019. For the prospective part, it is planned to include patients with same characteristics over the years 2024 and 2025. More than 2,500 patients are expected to be included.\n\nThis research will have no impact on current patient care. Data from consultations and various examinations carried out as part of care will be collected for six months post-diagnosis in order to meet the research objectives.",[435],"Pulmonary Embolism",[437,438,439],"Acute Pulmonary Embolism","Clustering with unsupervised learning","Therapeutic decision tool",{"date":38,"type":39},{"date":442,"type":39},"2023-12-11",{"date":444,"type":21},"2026-07-01",{"name":45,"class":46},{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":47},"100594225","efficacy-of-therapy-with-prp-injections-versus-ha-in-patients-with-advanced-grade-of-gonarthrosis-100594225","NCT07016672","Efficacy of Therapy With PRP Injections Versus HA in Patients With Advanced Grade of GONArthrosis","Efficacy of Therapy With Intra-articular Injections of PRP Compared With Therapy With Intra-articular Injections of HA, in Patients With Grade III or IV GONArthrosis: a Prospective Randomized Open-label Study","PAGONA","Inclusion Criteria:\n\n1. Age ≥ 18 years ;\n2. MRI confirmed grade III or IV unilateral gonarthrosis ;\n3. Pain ≥ 3\u002F10 on the visual analogue scale (VAS);\n4. Patient with a BMI \\\u003C 35\n5. Patient capable of giving consent prior to participation in the study;\n6. Affiliated or entitled under a social security scheme.\n\nExclusion Criteria:\n\n1. Non-steroidal anti-inflammatory drugs\\* or corticosteroids\\*\\* taken in the 7 days prior to inclusion;\n2. Local injection of hyaluronic acid in the 2 months prior to inclusion;\n3. Local injection of PRP within 1 year prior to inclusion;\n4. Local injection of corticosteroids within 5 months prior to inclusion;\n5. Current anticoagulant treatment that cannot be stopped during the hyaluronic acid or PRP injection protocol period;\n6. Patient diagnosed with any type of cancer in the last 3 years;\n7. Pregnant women, women in labour or breast-feeding women;\n8. Patients under judicial protection (guardianship, curatorship, etc.) or safeguard of justice;\n9. Any other reason which, in the opinion of the investigator, could interfere with the evaluation of the study objectives.\n\n   * Acetylsalicylic acid is allowed when it is prescribed as an antiplatelet agent at doses lower than or equal to 160 mg per day. It has, indeed, no anti-inflammatory effect at these doses.\n\n     * Corticosteroids can be administered when they have a local action different from the one applied to the treated knee (cutaneous, instiled or inhaled routes).",{"count":455,"type":21},150,[24],"Gonarthrosis is a chronic pathology affecting the knee joint and tissues. It is characterized by progressive degeneration of articular cartilage, bone and surrounding structures. Diagnosis is based on clinical, biological and radiological criteria.\n\nWhen knee osteoarthritis becomes symptomatic, it leads to pain associated with stiffness and functional discomfort, impacting on patients' quality of life. Patients become sedentary and isolated, which has cardiovascular and psychological consequences, with a proven excess mortality rate.\n\nTo date, there are no curative treatments for gonarthrosis. Available treatments are generally aimed at relieving pain, improving joint function and slowing disease progression. Therapeutic approaches most often combine non-pharmacological treatments such as dietary measures, regular physical activity and therapeutic education, with pharmacological treatments: paracetamol, non-steroidal anti-inflammatory drugs, opioids, intra-articular injections of corticosteroids, hyaluronic acid (HA), Platelet Rich Plasma (PRP)... If these are ineffective, particularly in advanced stages (grades III-IV), then surgery for prosthesis is necessary. However, surgery is not an option for all patients, particularly those with co-morbidities, the elderly or those who refuse it.\n\nThe osteoarthritis section of the French rheumatology society has drawn up recommendations, with a view to positioning these treatments, standardizing practices and improving the management of gonarthrosis patients in France. These point out that further studies are needed to validate the efficacy of certain treatments, notably intra-articular PRP injections, which are nevertheless widely used in current practice and defended by a consensus of French experts published in 2021. Indeed, the results of several therapeutic trials and meta-analyses already published show that its efficacy is often superior to that of HA, particularly in terms of symptom improvement and over a longer duration. In order to make the case for their use to learned societies, literature data must be enriched, particularly with regard to advanced stages of gonarthrosis, i.e. stages III-IV, which are the most painful. The aim is to propose an effective treatment to relieve the symptoms of patients for whom surgery is not an option.",[459],"Knee Osteoarthritis",[461,462,463,464,465,466],"Pain","Functional impact","Platelet Rich Plasma","hyaluronic acid","Intra-articular injection","Advanced grade","2026-06-11",{"date":469,"type":39},"2026-06-12",{"date":471,"type":39},"2025-09-18",{"date":473,"type":21},"2028-10",{"name":45,"class":46},{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":127,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":494,"leadSponsor":496,"locationsCount":47},"100643275","moral-injury-study-among-healthcare-professionals-in-psychiatric-facilities-in-the-paca-region-100643275","NCT07631741","Moral Injury Study Among Healthcare Professionals in Psychiatric Facilities in the PACA Region","A Mixed Epidemiological Study of Moral Injury Among Healthcare Professionals in Psychiatric Facilities in the PACA Region","MI-PSY","Inclusion Criteria:\n\n* Healthcare Professionals working on Psychiatric Facilities in the PACA Region\n\nExclusion Criteria:\n\n* Absence of consent",{"count":484,"type":21},2688,"Healthcare professionals working in psychiatric settings face demanding working conditions characterized by high rates of burnout and specific constraints, such as the deprivation of patients' liberty. \\*Moral Injury\\* (MI), a relatively recent concept, extends beyond burnout by focusing on the distress arising from ethical conflicts and the dissonance between professional values and the realities of clinical practice. Although the concept has begun to emerge from a theoretical perspective, particularly in the United States, it remains largely unknown in France and has yet to be investigated in psychiatric settings at the international level.\n\nThe hypothesis is that MI plays a central role in healthcare professionals' psychological distress and contributes to the major recruitment and retention crisis affecting public psychiatric institutions. This crisis is reflected, for example, in a 40% vacancy rate for hospital physician positions in public facilities, with particularly acute shortages in child and adolescent psychiatry. The demographic crisis in child and adolescent psychiatry is unprecedented, marked by a 30% decline in the workforce over the past decade and projections suggesting a further 50% reduction within the next ten years. At the same time, mental health disorders among adolescents-particularly suicide attempts among girls-have increased substantially since the COVID-19 pandemic.\n\nThis study aims to explore the organizational, individual, and systemic factors associated with Moral Injury in order to better understand and prevent this form of professional suffering.",[203],[203,206,488,489],"Healthcare Professionals","Psychiatry","2026-06-08",{"date":492,"type":39},"2026-06-10",{"date":444,"type":21},{"date":495,"type":21},"2026-12-31",{"name":45,"class":46},""]